Loading…
Biodesix, Inc. is projected to rise to $23.59 by 2027, a +59% move from its current price of $14.81. BDSX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.17 | $14.82 | $15.49 | +0.06% |
| May 30 | $13.92 | $14.83 | $15.79 | +0.12% |
| May 31 | $13.73 | $14.84 | $16.03 | +0.18% |
| Jun 1 | $13.58 | $14.85 | $16.23 | +0.24% |
| Jun 2 | $13.45 | $14.85 | $16.41 | +0.30% |
| Jun 3 | $13.33 | $14.86 | $16.58 | +0.36% |
| Jun 4 | $13.22 | $14.87 | $16.73 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.22 | $14.87 | $16.73 | +0.42% |
| Week 2 | $12.64 | $14.94 | $17.64 | +0.84% |
| Week 3 | $12.23 | $15.00 | $18.39 | +1.27% |
| Week 4 | $11.90 | $15.06 | $19.07 | +1.70% |
| Week 5 | $11.62 | $15.12 | $19.69 | +2.12% |
| Week 6 | $11.38 | $15.19 | $20.27 | +2.55% |
| Week 7 | $11.17 | $15.25 | $20.83 | +2.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories.
The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Biodesix, Inc. (BDSX) is a healthcare stock with a current price of $14.93 and a market cap of $154.61M. It is ranked 4007 in market capitalization.
The forecast shows a path of upside over the coming years, with the 2026 average price at $14.93 (ROI 0%) and a bullish trajectory evident in subsequent years. The projected averages rise through the late 2020s and into the 2030s, with the 2030 average at $27.97 and the 2034–2050 window showing substantial upside.
By 2030 the average price is projected at $27.97 with a projected maximum of $46.95 and an 87.4% ROI, while by 2050 the average reaches $145.11 and the maximum $333.76 with an 872% ROI. The long-term outlook is described as BULLISH across multiple years.
Overall, the forecast presents a bullish price path with meaningful upside potential in the care of long-run price levels, though estimates are not guarantees and reflect market conditions within the model’s inputs.
A major floor 50.6% below — a decisive break under it would weaken the trend.
The nearest floor, 33.6% below — buyers have tended to step in here.
The nearest ceiling, 8.8% above — a clean break opens room to run.
A major ceiling 34.1% above — clearing it would confirm fresh momentum.
Key BDSX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDSX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.82 | Sell | $14.77 | Buy |
| MA 10 | $14.59 | Buy | $14.62 | Buy |
| MA 20 | $14.08 | Buy | $14.23 | Buy |
| MA 50 | $13.83 | Buy | $13.73 | Buy |
| MA 100 | $12.81 | Buy | $12.76 | Buy |
| MA 200 | $10.24 | Buy | $12.12 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.81 | Neutral |
| Stoch RSI (14) | 29.69 | Neutral |
| CCI (20) | 36.56 | Neutral |
| Williams %R (14) | -59.91 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -3.33 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 40.09 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 1.56 | Buy |
| Ultimate (7,14,28) | 59.34 | Neutral |
| Momentum (10) | -0.94 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 15.06 | Sell |
| ADX (14) | 17.32 | Neutral |
| ATR (14) | 0.49 | Info |
The 30-day technical picture shows a bullish bias with RSI 14 at 60, indicating modest positive momentum.
Biodesix trades above the SMA50 of $13.94 and well above the SMA200 of $10.18, suggesting a constructive short-term trend. Key levels to watch are support at $9.84 and resistance at $16.11.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.46 | $14.81 | $24.75 | 0% | Neutral | |
| $17.57 | $23.59 | $34.13 | +59% | Bullish | |
| $19.38 | $27.30 | $41.66 | +84% | Bullish | |
| $20.98 | $30.78 | $48.96 | +108% | Bullish | |
| $19.85 | $30.22 | $49.76 | +104% | Bullish | |
| $21.75 | $34.24 | $58.12 | +131% | Bullish | |
| $22.49 | $36.58 | $63.77 | +147% | Bullish | |
| $25.87 | $43.38 | $77.48 | +193% | Bullish | |
| $36.25 | $62.63 | $114.35 | +323% | Bullish | |
| $35.98 | $63.99 | $119.23 | +332% | Bullish | |
| $48.49 | $98.86 | $200.43 | +568% | Bullish | |
| $84.55 | $187.90 | $429.54 | +11.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.46 | $14.81 | $17.44 | +0.00% |
| June 2026 | $12.27 | $14.61 | $17.95 | -1.36% |
| July 2026 | $12.96 | $15.64 | $19.64 | +7.08% |
| August 2026 | $13.26 | $16.19 | $20.66 | +3.50% |
| September 2026 | $12.96 | $15.96 | $20.64 | -1.42% |
| October 2026 | $13.56 | $16.84 | $22.04 | +5.50% |
| November 2026 | $14.64 | $18.33 | $24.24 | +8.83% |
| December 2026 | $14.71 | $18.54 | $24.75 | +1.14% |
Click any year to see its month-by-month BDSX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BDSX is projected to trade between $5.46 and $24.75, averaging $14.81 — a potential gain of 0% from today's $14.81. Price action looks broadly range-bound.
Biodesix, Inc.'s 2027 outlook centres on $23.59, within a $17.57 to $34.13 range. That is up +59% on the projected 2026 average. That marks a +59% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, BDSX could reach as high as $41.66, with a base case around $27.30 and support toward $19.38 — roughly +84% from $14.81. Momentum favours further upside here.
Expect BDSX to range from $20.98 to $48.96 through 2029. The $30.78 average target implies a +108% move from current prices. That is up +13% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BDSX price prediction for 2030 points to an average of $30.22 (low $19.85, high $49.76) — a potential gain of +104% on today's $14.81. Momentum favours further upside here.
In 2031, BDSX is projected to trade between $21.75 and $58.12, averaging $34.24 — a potential gain of +131% from today's $14.81. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Biodesix, Inc.'s 2032 outlook centres on $36.58, within a $22.49 to $63.77 range. That is up +7% on the projected 2031 average. That marks a +147% change versus current levels. Momentum favours further upside here.
By 2033, BDSX could reach as high as $77.48, with a base case around $43.38 and support toward $25.87 — roughly +193% from $14.81. Buyers look set to stay in control over this stretch.
Expect BDSX to range from $36.25 to $114.35 through 2034. The $62.63 average target implies a +323% move from current prices. That is up +44% on the projected 2033 average. Momentum favours further upside here.
The BDSX price prediction for 2035 points to an average of $63.99 (low $35.98, high $119.23) — a potential gain of +332% on today's $14.81. Buyers look set to stay in control over this stretch.
In 2040, BDSX is projected to trade between $48.49 and $200.43, averaging $98.86 — a potential gain of +568% from today's $14.81. That is up +54% on the projected 2035 average. Momentum favours further upside here.
Biodesix, Inc.'s 2050 outlook centres on $187.90, within a $84.55 to $429.54 range. That is up +90% on the projected 2040 average. That marks a +11.7x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BDSX today (≈ 67.521945 BDSX) could be worth
$12,687.33
+$11,687.33 (+1169%) by 2050 · US Dollar
Based on the average projected BDSX price of $187.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDSXwould be worth at today's price.
$1,000 invested in BDSX on May 27, 2025 (≈ 144.508669 BDSX) would be worth
$2,140.17
+$1,140.17 (+114.0%) today · 2.14× · US Dollar
Based on a BDSX entry price of $6.92 vs. today's $14.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.37 | $1,030.62 | +3.1% |
| 1 month ago | $10.13 | $1,462.72 | +46.3% |
| 3 months ago | $14.22 | $1,041.49 | +4.1% |
| 6 months ago | $8.28 | $1,788.65 | +78.9% |
| 1 year ago | $6.92 | $2,140.17 | +114.0% |
| All time (5.0y) ago | $298.6 | $49.6 | -95.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDSX forecast.
Our base-case forecast reaches $30.00 around 2029.
Implied market cap at $30.00: $310.67M
The year-by-year forecast outlines a steady, bullish trajectory beyond 2026. The 2026 forecast shows min $5.46, avg $14.93, max $24.53 with ROI 0 and neutral sentiment. From 2027 onward, sentiment is BULLISH with the avg price increasing to $23.11 (2027), $26.34 (2028), and $28.90 (2029), with ROI of 54.8%, 76.4%, and 93.6% respectively.
By 2030, the avg is $27.97 with a max of $46.95 and ROI 87.4%, and by 2031–2032 the avg moves to $30.69 and $31.34 with max values above $50 and ROI of 105.5% and 109.9%. The forecast continues to rise, with 2033 at an average of $36.87 and 2034 at $54.00 (max $100.90, ROI 261.7), and 2035 at $54.20 (max $103.44, ROI 263).
In the longer horizon, 2040 shows an average of $78.86 with a max of $164.26 and ROI 428.2, and 2050 shows an average of $145.11 with a max of $333.76 and ROI 872, all described as BULLISH. The volatility level implied by the forecast remains high (annualized volatility 90%), and the results are not guaranteed and depend on market conditions.
Tap a question to reveal the answer.
The 2030 forecast lists min $17.99, avg $27.97, max $46.95 with ROI 87.4% and sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with ROI rising from 54.8% (2027) to 872% (2050), though the 2026 ROI is 0% and estimates are not guaranteed.
Yes. The 2034 max is $100.90, and the 2040 max is $164.26, with the 2050 max at $333.76, indicating a path above $100 by mid-decade under the forecast.
Current price is $14.93 and market cap is $154.61M.
Bullish sentiment with RSI 14 at 60. SMA50 is $13.94 and SMA200 is $10.18. Support is at $9.84 and resistance at $16.11. The 30-day range is $10.93–$20.40 with annualized volatility of 90%.
Biodesix, Inc. Community Discussion
0Share your Biodesix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.